NASDAQ · MIRA
Healthcare · Drug Manufacturers - General
$0.76
Up+$0.02 (+3.27%)
Updated Sep 6, 2026, 9:40 AM
SID Score
3.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
MIRA closed at $0.76 after 20 trading sessions, down 0.44% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $0.7351 | $0.8498 | $0.7351 | $0.7638 | 338.53K |
| Sep 3, 2026 | $0.83 | $0.84 | $0.7313 | $0.7396 | 494.95K |
| Sep 2, 2026 | $0.857 | $0.9349 | $0.8247 | $0.8495 | 581.84K |
| Sep 1, 2026 | $0.74 | $1.10 | $0.7212 | $0.86 | 29.28M |
| Aug 31, 2026 | $0.75 | $0.7816 | $0.75 | $0.7702 | 44.34K |
| Aug 28, 2026 | $0.75 | $0.7794 | $0.75 | $0.7501 | 31.85K |
| Aug 27, 2026 | $0.75 | $0.778 | $0.74 | $0.7701 | 44.12K |
| Aug 26, 2026 | $0.7701 | $0.7741 | $0.75 | $0.75 | 27.37K |
| Aug 25, 2026 | $0.80 | $0.81 | $0.7682 | $0.7753 | 35.3K |
| Aug 24, 2026 | $0.779 | $0.8248 | $0.7702 | $0.7881 | 65.13K |
| Aug 21, 2026 | $0.72 | $0.82 | $0.72 | $0.7636 | 117.4K |
| Aug 20, 2026 | $0.7701 | $0.7958 | $0.7101 | $0.7101 | 41.65K |
| Aug 19, 2026 | $0.7601 | $0.7998 | $0.7601 | $0.7701 | 41.1K |
| Aug 18, 2026 | $0.765 | $0.7949 | $0.7601 | $0.7645 | 40.61K |
| Aug 17, 2026 | $0.80 | $0.81 | $0.7738 | $0.79 | 59.97K |
| Aug 14, 2026 | $0.782 | $0.8106 | $0.7655 | $0.7802 | 75.48K |
| Aug 13, 2026 | $0.77 | $0.825 | $0.75 | $0.7501 | 83.81K |
| Aug 12, 2026 | $0.7725 | $0.7851 | $0.7383 | $0.7387 | 26.54K |
| Aug 11, 2026 | $0.803 | $0.803 | $0.7705 | $0.7777 | 18.57K |
| Aug 10, 2026 | $0.759 | $0.7899 | $0.741 | $0.7672 | 114.14K |
The latest Smart Investors Daily articles mentioning MIRA.
MIRA research
Company profile and research snapshot.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 30, 2024 | Rodman & Renshaw | Buy | — |
| Aug 5, 2024 | Ascendiant Capital | Buy | — |
No generated briefing is available yet.
Benzinga · Mar 3, 2026
https://www.sec.gov/ix?doc=/Archives/edgar/data/1904286/000149315226008707/form8-k.htm
Benzinga · Feb 3, 2026
Phase 1 Progress and Phase 2a Development PlansThe ongoing randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, and pharmacokinetics of single and multiple oral
Benzinga · Feb 2, 2026
SEC Filing.
accessnewswire.com · Oct 24, 2025
Advancing toward Phase 2a clinical evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track consideration MIAMI, FLORIDA / ACCESS Newswire / October 24, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel oral therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced the initiation of the multiple ascending dose (MAD) portion of its ongoing Phase 1 clinical trial evaluating its lead oral candidate, Ketamir-2, in healthy volunteers. The Company also announced that it has selected chemotherapy-induced peripheral neuropathy (CIPN) - a common and debilitating side effect of cancer treatment - as the lead indication for its planned Phase 2a clinical evaluation.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MIRA.
